2 October 2026 · The Pharmacist
MHRA approves elinzanetant for VMS in breast cancer therapy
The Medicines and Healthcare products Regulatory Agency (MHRA) has extended the licence for elinzanetant, making it the first medicine specifically licensed in the UK to treat moderate to severe vasomotor symptoms in women receiving adjuvant endocrine therapy for breast cancer. Vasomotor symptoms typically include hot flushes and night sweats, which are commonly associated with menopause and frequently experienced by patients undergoing endocrine-based cancer treatments.
Under this extended authorisation, elinzanetant gains an official indication for managing these symptoms specifically within this patient group. While comprehensive details regarding the underlying clinical submission and wider distribution timelines remain limited in the initial regulatory notice, the approval establishes a dedicated licensed pharmacological option for patients dealing with treatment-related hot flushes.
Healthcare providers and digital dispensing services should look out for the publication of updated product literature and relevant clinical guidance before integrating the newly licensed indication into regular practice. Prescribing teams must ensure that patient assessment pathways align strictly with the approved therapeutic scope, dosing recommendations, and any defined clinical criteria.
For UK online pharmacies and prescribing brands, this licence extension will likely require review and potential updates to clinical consultation workflows and formulary listings once full prescribing information is accessible.